Clinical Phenotype and Prognosis of Real-World Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
European Journal of Heart Failure · 2025
DOI: 10.1002/ejhf.70071 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Aldostefano Porcari und 48 weiteren Autor:innen. Beteiligte Einrichtung: Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), Univers…. Hauptthemen laut MEDLINE: Benzoxazoles, Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Ministero della Salute.
Abstract (Originalsprache)
Aims
Tafamidis reshaped the treatment paradigm in transthyretin amyloid cardiomyopathy (ATTR-CM) based on a phase-3 randomized controlled trial, but real-world data on its use remain limited. This study aimed to assess in a large, contemporary, real-world cohort of patients with wild-type ATTR-CM (ATTRwt-CM) (i) the clinical phenotype of patients receiving tafamidis, and (ii) the association of tafamidis with survival using propensity-matched observational data. Methods and results Data of patients diagnosed with ATTRwt-CM (January 2017 to June 2023) from 19 Italian centres were analysed. A propensity score (PS) reflecting the likelihood of being treated with tafamidis for each patient was determined using four variables that were significantly different among the two groups: age, New York Heart Association (NYHA) class, National Amyloidosis Centre (NAC) stage and mineralocorticoid receptor antagonists (MRAs). The primary outcome was all-cause mortality. The study comprised 1556 ATTRwt-CM patients: 965 (62%) patients initiated on tafamidis by June 2023 and 591 (38%) patients never treated with disease-modifying therapy. Tafamidis-treated patients were older, exhibited a lower NYHA class and NAC stage, and were more often treated with MRAs compared to untreated patients. The PS-matched cohort comprised 426 patients treated with tafamidis and 426 PS-matched untreated patients (mean age 78.9 ± 5.0 years, 88.3% men, 12.9% in NYHA class III). Adequacy of matching was verified (standardized differences: <0.20 between groups). Over 25 months (interquartile range: 15–40), treatment with tafamidis was associated with lower rates of all-cause mortality (hazard ratio 0.55, 95% confidence interval 0.39–0.77, p = 0.001) across the spectrum of NAC disease stages (p-interaction = 0.94).
Conclusions
In this large, contemporary, real-world cohort of patients with ATTRwt-CM, predominantly in NYHA class I or II, treatment with tafamidis was consistently associated with a significantly lower risk of all-cause mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy.
- European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart, ERN GUARD-Heart, Trieste, Italy.
- National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, UK.
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.
- Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
ORCID-Profile: Aldostefano Porcari
Förderung
- Italian Ministry of Health
- Ministero della Salute
Zitieren
APA
Porcari, A., Milani, P., Longhi, S., Cappelli, F., Vagnarelli, F., Aimo, A., Cipriani, A., Gardini, E., Marazia, S., Monda, E., Tini, G., Musumeci, B., Serenelli, M., Cantone, A., Lofiego, C., Marini, M., Vergaro, G., Foti, G., Musca, F., …, & Sinagra, G. (2025). Clinical Phenotype and Prognosis of Real-World Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.70071
Vancouver
Porcari A, Milani P, Longhi S, Cappelli F, Vagnarelli F, Aimo A, et al. Clinical Phenotype and Prognosis of Real-World Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.70071
BibTeX
@article{Porcari2025,
author = {Porcari, Aldostefano and Milani, Paolo and Longhi, Simone and Cappelli, Francesco and Vagnarelli, Fabio and Aimo, Alberto and Cipriani, Alberto and Gardini, Elisa and Marazia, Stefania and Monda, Emanuele and Tini, Giacomo and Musumeci, Beatrice and Serenelli, Matteo and Cantone, Anna and Lofiego, Carla and Marini, Marco and Vergaro, Giuseppe and Foti, Grazia and Musca, Francesco and Tomasoni, Daniela and Bonacchi, Giacomo and Colio, Federica and Sinigiani, Giulio and De Michieli, Laura and Sturdà, Francesca and Pozzan, Marco and Gentile, Piero and Carigi, Samuela and Bartolotti, Michela and Sena, Giuseppe and Ruotolo, Irene and Sanna, Giuseppe Damiano and Zanoletti, Margherita and Canepa, Marco and Di Marco, Massimo and D'Elia, Emilia and Di Bella, Gianluca and Driussi, Mauro and Imazio, Massimo and Perfetto, Federico and Biagini, Elena and Limongelli, Giuseppe and Metra, Marco and Emdin, Michele and Merlini, Giampaolo and Perlini, Stefano and Merlo, Marco and Palladini, Giovanni and Sinagra, Gianfranco},
title = {Clinical Phenotype and Prognosis of Real-World Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis},
journal = {European Journal of Heart Failure},
year = {2025},
doi = {10.1002/ejhf.70071}
}
EUVIMED